Premium
Positron emission tomography radioligands for in vivo imaging of A β plaques
Author(s) -
Mason N. Scott,
Mathis Chester A.,
Klunk William E.
Publication year - 2013
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2989
Subject(s) - positron emission tomography , chemistry , drug development , preclinical imaging , pet imaging , nuclear medicine , in vivo , medical physics , molecular imaging , pharmacology , drug , medicine , microbiology and biotechnology , biology
The development of positron emission tomography (PET) radioligands for the non‐invasive imaging of amyloid‐ β plaque burden has been the focus of intense research efforts over the last decade. A variety of structural backbones have been investigated and several radiolabeled molecules have been evaluated in phase I (and later) clinical studies. These efforts have been driven by the desire not only to develop a suitable diagnostic imaging agent but also to develop a means to evaluate potential therapies for Alzheimer's disease. This review focuses on the development of these ligands, as well as the radiochemistry and current regulatory status of these PET radioligands. Particular attention is given to those ligands that have progressed to the later stages of drug development (phase II/III clinical trial studies) or approved New Drug Application status.